Mednet Logo
HomeQuestion

How does trimethoprim-sulfamethoxazole's efficacy against S. pyogenes influence your empirical treatment of skin infections in regions with high resistance rates?

1
3 Answers
Mednet Member
Mednet Member
Infectious Disease · Zucker School of Medicine at Hofstra / Northwell

Recommendations against using trimethoprim-sulfamethoxazole (TMP/SMX) for group A strep (GAS) skin and soft tissue infections (SSTIs) likely stemmed from a misconception that GAS is inherently resistant to the drug. Older studies reporting resistance used media containing a high thymidine concentrat...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Infectious Disease · Cooperman Barnabas Medical Center

I am a little confused by the question. Why would you use TMP/SMX monotherapy for SSTI? During the emergence of CA-MRSA, cephalexin with or without TMP/SMX had the same efficacy rates (Pallin). I agree with Dr. @Dr. First Last; linezolid is a great choice if MRSA is a concern. Cephalexin or cefadrox...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Infectious Disease · Cooperman Barnabas Medical Center

Why I Still Don’t Understand Using TMP/SMX for SSTIs.

TMP/SMX has poor clinical activity against Gram-positive cocci to begin with. But the bigger issue is how it’s almost always dosed in practice. For SSTIs, Doctors prescribe Bactrim DS, 1 PO BID— the appropriate dose for cystitis, but nowhere near...

Register or Sign In to see full answer